Loading...
  • polycythemia
  • Depending on the nature of the myeloproliferative neoplasm, diagnostic tests may include red cell mass determination (for polycythemia), bone marrow aspirate and trephine biopsy, arterial oxygen saturation and carboxyhaemoglobin level, neutrophil alkaline phosphatase level, vitamin B 12 (or B 12 binding capacity), serum urate or direct sequencing of the patient's DNA. (wikipedia.org)
  • gene
  • Tissue factor (TF) can also stimulate the transcription of the gene encoding VEGF-A. The relationship between coagulation and angiogenesis in myeloproliferative neoplasms is not fully understood. (mdpi.com)
  • liver
  • An exam of the body to check general signs of health, including checking for signs of disease such as an enlarged spleen and liver. (wellspan.org)
  • entities
  • The revision of the fourth edition follows the philosophy of the third and fourth editions to incorporate clinical features, morphology, immunophenotyping, cytogenetics, and molecular genetics to define disease entities of clinical significance. (bloodjournal.org)
  • Myeloid disease that shows features of both MDS and CMPD but does not meet the criteria for any of the three major MDS/MPN entities is designated as myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC). (cigna.com)
  • treatments
  • Pharmacologic as well as nonpharmacologic treatments of the inflammatory component of this disease may lead to decreased symptomatic burden, prevention of disease progression, and improvement in overall disease trajectory. (springer.com)
  • Are There MPN Treatments That Reduce Fibrosis and Slow Disease Progression? (patientpower.info)
  • Dr. Verstovsek explains the how the treatments work and discusses the possibility of reducing fibrosis and limiting disease progression. (patientpower.info)
  • criteria
  • An international consortium has proposed uniform response criteria to be used in clinical trials because of the spectrum of presentations ranging from the myelodysplastic to the myeloproliferative. (cigna.com)
  • An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. (cigna.com)